Newborn Screening for Rare and Treatable Diseases in 2025

Value of the Information & Strength of the Argument

The video provides valuable insights into the current state of newborn screening, combining personal advocacy experience with scientific expertise. Dean Suhr’s argumentation is compelling, using his family’s story to illustrate the impact of screening delays. He effectively argues for the need to adapt to policy changes and seize opportunities. Michael Gelb’s presentation is scientifically rigorous, explaining complex assay technologies in an accessible manner. He presents unpublished data on sequencing-based screening, which adds novelty. However, some claims lack direct citations, and the argumentation is sometimes more anecdotal than systematic.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, with both speakers demonstrating deep knowledge. Suhr references the National Academies report and specific policy changes, while Gelb discusses his own research and published assays. The sources cited are primarily from the speakers’ own work and general knowledge, with limited external references. The title accurately reflects the content, which is focused on the 2025 landscape of newborn screening. The video includes a brief promotional segment for PNRI’s Science Matters series, but it does not detract from the content.

The title accurately reflects the content, which covers the current state of newborn screening for rare diseases in 2025, including policy and technology.

8/10

The video features two expert speakers with deep involvement in newborn screening: a patient advocate and a biochemist who developed assays. They provide detailed, up-to-date information on policy changes and technological advances. However, the content is largely based on personal experience and opinions, with limited peer-reviewed citations.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction to the seminar and speakers.
• 10:00Dean Suhr begins his presentation on newborn screening policy and MLD.
• 30:00Discussion of the RUSP and the impact of the ACHDNC disbandment.
• 45:00Michael Gelb starts his talk on assay development and sequencing.
• 1:00:00Gelb discusses new technologies and unpublished data on sequencing.
• 1:15:00Q&A session and concluding remarks.

• PNRI Science Matters Events — Mentioned as a resource for upcoming seminars.

• National Academies Report on Newborn Screening — Referenced by Suhr as a recent independent report.